yabar_et

INTRODUCTION

Oral mucosa lesions could be presented as changes in color, appearance, swelling or loss of the integrity of the tissue surface. Some types of these lesions may be benign and do not require any treatment, others may present acute symptoms, affecting patient’s quality of life, causing difficulties with swallowing and speech, with symptoms such as burning, irritation and pain (1). The prevalence of oral lesions in the general population worldwide ranges from 4.9% to 64.7% (2, 3).

The oral mucosa could be an easily accessible point of entry for infectious agents, such as bacteria or viruses. Therefore, an early diagnosis and treatment is essential to avoid future complications or the development of serious, even malignant lesions (4). There are several alternatives for conventional treatment according to the type of mucosal lesion the patient has, however, some of these have been shown to be inefficient, by generating discomfort to the patients and requiring relatively extended treatment times. In view of the foregoing, there are treatment alternatives in natural and traditional medicine that are used as therapy for oral diseases, such as ozone therapy that has shown some positive findings (5).

Ozone is a natural gaseous molecule formed by 3 oxygen atoms. Ozone has been recognized for being immunostimulant, analgesic, anti-hypnotic, detoxifying, antimicrobial, and being capable of performing bioenergetic and biosynthetic actions. Due to its atraumatic, painless, non-invasive characteristics, it can be considered highly reliable and has shown a high acceptance rate among patients (6). There are 3 ways to apply ozone: ozone gas, ozonated water and ozonated oil (7).

Ozonated oil results from the reaction of ozone with fatty acids and other substances, by means of bubbling ozone through of a generator. During this reaction, substances such as peroxides, ozone, aldehydes and ketones are formed (8, 9). Ozonated oil that comes into contact with exudates or injuries is divided and generates ozone, releasing hydrogen peroxide and lipoperoxides, promoting regenerative and disinfectant effects. This slow release of ozone further promotes the healing process by acting as a local antimicrobial agent and promoting cytokine release with an effect on tissue repair (10).

There are many studies where ozonated oil has been used as a therapeutic agent for different types of oral lesions, showing better results than control conventional treatments. Some benefits described in the literature include quicker healing, less discomfort and absence adverse effects (5, 11-22). However, there is no standardized methods to apply it, benefits or the ideal treatment time. Therefore, a systematic review was conducted to answer the following focused question based on a PICO strategy: Is the use of ozonated oil effective in the treatment of ulcerated lesions of the oral mucosa? And: is the use of ozonated oil effective in the treatment of alveolar bone lesions?

MATERIALS AND METHODS

Protocol and registration

This SR was conducted in accordance to the Transparent Reporting of Systematic Reviews and Meta-Analysis-PRISMA Statement (23) and was registered at PROSPERO with number CRD42021237068.

Focused question

The focused questions to be addressed were:

1. Is the use of ozonated oil effective in the treatment of ulcerated lesions of the oral mucosa?

2. Is the use of ozonated oil effective in the treatment of alveolar bone lesions?

Eligibility Criteria

The inclusion criteria for this SR were the following: Clinical studies that used ozonated oil as a treatment for different oral lesions (subprosthetic stomatitis, recurrent aphthous stomatitis, herpetic gingivoestomatitis, pericoronaritis, alveolitis and fibroedematous gingivitis). Literature reviews, letters to the editor, short communications, case reports, pilot studies and trials that analyze other applications of ozonated acceptance not related to oral injuries were excluded.

Search strategy

The MEDLINE (PubMed), Embase, Cochrane Library, Scielo and LILACS databases were searched up to March 2021 by two independent reviewers (J.Y and J.A). The search was performed without restrictions on dates or language. The search strategy was applied as follows: PubMed: ("Aphthous stomatitis" OR "Dry Socket" OR "Pericoronitis" OR "Herpetic Stomatitis" OR "subprosthetic stomatitis" OR "fibro edematous" OR “alveolitis” OR osteomyelitis OR "Aphthous Ulcer" OR "Aphthous Stomatitides" OR "Alveolar Osteitis" OR "Herpetic Gingivostomatitis" OR "Oral Herpes Simplex" OR "oral injury" OR "oral lesion") AND ("ozonated oil" OR "Ozonated" OR "ozonation" OR "ozone" OR "Ozonized" OR "ozone therapy" OR "ozonotherapy" OR "ozonating" OR "oleozon" OR "vegetable oils" OR "plant oils" OR "ozonation"). In addition, the grey literature in the System for Information on Grey Literature in Europe (http://www.opengrey.eu) and Google Scholar databases were screened electronically, as recommended by the high standards for systematic reviews (AMSTAR guideline) (24). Finally, the list of references of studies included were also hand searched to capture any potential additional records, as suggested by Greenhalgh and Peacock (25).

Data collection, extraction

and management

Screening and selection of articles?

Titles and abstracts were screened by two independent reviewers (JY. and JA). Full-texts were obtained and reviewed for studies that appeared to meet the inclusion criteria. Kappa scores (Cohen’s Kappa coefficient) were used during full-text assessment to ensure eligibility and level of agreement between the reviewers. Disagreements were solved by discussion and consulting a third reviewer (GM).

Data extraction

The studies that fulfilled the eligibility criteria were processed for data extraction, conducted by two independent researchers, using predefined spreadsheets. Disagreements were resolved by discussion with a third reviewer. In the event of missing data, a request was sent to the authors by e-mail. For each study selected, the following variables were collected: 1) characteristics of the study: author, year of publication, country, design of the study (randomized clinical trial and non-randomized); 2) demographic data: sample size, mean age (years) and gender (male/female); 3) outcome measures: healing time, application interval and adverse effects (presence or absence).

Risk of bias in individual studies

Two reviewers (J.M.M and J.Y) evaluated the risk of bias in studies selected, using the Cochrane tool for risk of bias assessment, RoB 2 (version 2, available at: https://www.riskofbias.info/welcome/rob-2-0-tool/current-version-of-rob-2).

The authors of this SR decided to evaluate the result related to "assignment to the intervention (the effect for the purpose of treating)" and five domains were examined: randomization bias and treatments concealment, bias due to deviations from the planned interventions that affected the involvement of the participants and a team of researchers, although there were missing result data, the result measurement and the result selection were selected. Based on the responses to the questions and the algorithms of the tool, it was considered that each domain had “low risk of bias”, "some concerns related to risk of bias" or "high risk of bias". The studies were categorized as low risk of bias (all domains had low risk of bias), high risk of bias (one or more domains had high risk of bias) and concerning (when one or more domains had some concerns) (26). The decisions were resolved by means of discussion, consulting a third advisor (G.M).

The non-randomized controlled trials were evaluated by means of the ROBINS-I tool. (27) Each controlled trial was classified as low information, or as low, moderate, severe and critical risk of bias. The discrepancies between the reviewers were resolved by means of open discussion. In the event that an agreement could not be achieved, the final decision was made by another co-author (G.M).

The following domains have evolved to not randomized controlled trials (27):

Preintervention

Confusion bias

Selection bias

Intervention

Bias in the classification of interventions

Post-intervention

Bias due to deviations from planned interventions

Bias due to missing data

Bias in the results measurement

Bias in the selection of the informed result

To demonstrate the general risk of bias, each study included was classified as low, moderate, severe and critical risk of bias or the absence of information according to the following criteria:

Low risk of bias: the study is considered to have a low risk of bias for all domains.
Moderate risk of bias: the study is considered to have a low to moderate risk of bias for all domains.
Severe risk of bias: the study is considered to have a severe risk of bias for at least one domain, but it does not have a critical risk of bias for any domain.
Critical risk of bias: the study is considered to have a critical risk of bias in at least one domain.
No information: there is no clear indication that the study has a serious or critical risk of bias and there is a lack of information on the most key domains for bias (a judgment is required for this).

RESULTS

Study Selection

The electronic search strategy identified 1957 articles. After analyzing the titles and abstracts, 1932 studies were excluded, the remaining 25 were subject of a full text exhaustive evaluation, from which 12 were excluded. As a result, 13 papers were included in this SR (Figure 1).

Study characteristics

The thirteen randomized (5, 11, 12, 14, 16, 18-20) and non-randomized clinical trials (13, 15, 17, 21, 22) included were conducted between 2010 and 2020, and their main methodological characteristics are presented in Table 1. All clinical studies showed the effective outcome of the ozonated oil on different types of oral lesions: subprosthetic stomatitis, recurrent aphthous stomatitis, herpetic gingivostomatitis, pericoronitis, alveolitis and fibro edematous gingivitis; and used as a control and conventional treatment for each type of oral lesion. A total of 1644 patients from different age groups were included in the present SR. Participants in 3 studies suffering from pericoronitis (11, 12, 22), participants in 3 studies developing alveolitis (5, 18, 22), 5 studies conducted in patients with recurrent aphthous stomatitis (14, 16, 19, 21, 22), 3 studies based on subprosthetic stomatitis (15, 17, 22), 2 studies were based on patients with fibroedematous gingivitis (20, 22), lastly a single study contemplating the use of ozonated oil for patients with herpetic gingivostomatitis (13). In all studies the local application of ozonated oil was used as therapy. The follow-up periods varied from 72 hours to 6 weeks, depending on the type of wound.

Ozonated oil in pericoronitis

In 2 randomized clinical trials (RCT) (11, 12) and 1 non-RCT(22) authors reported the use of the ozonated oil as therapy for pericoronitis and compared it with conventional therapy consisting of 50% trichloroacetic acid and mouthwashes with 0.2% chlorhexidine for a period of time between 3 to 7 days, an interval of application was 3 to 4 times a day, with a healing time between 72 hours and 7 days, a larger number of patients recovered in less time in the study group (ozonated oil), while the control groups showed lower satisfaction rates in the same period of time, showing statistically significant differences. No adverse effects were reported.

Ozonated oil in alveolitis

In 2 RCT (5, 18) and 1 non RCT (22) Ozonated oil treatment was used as a treatment for alveolitis and compared it with alvogyl. All the studies had a 7-day follow-up period, the time interval in which the healing took place. The lesions healing times were heterogeneous, varying between 4 days (18), 5 days (5) or up to 7 days (22) for study group (ozonated oil), the interval of application varied from 4 times a day (22) up to every 72 hours (5), no adverse effects were reported. In all cases, a shorter recovery time was observed when Ozonated oil was used as therapy. However, only one study (5) reported statistically significant differences.

Ozonated oil in fribroedematous gingivitis

Only 2 studies: 1 RCT (20) and 1 non-RCT (22), used the Ozonated oil therapy for fibroedematous gingivitis and it was compared with the use of chlorhexidine mouthwashes at 0.2%, the healing time varied between 7 days (22) showing only favorable results in study group (ozonated oil) and 6 weeks (20) (in which 96.6% of patients healed in the study group), the interval of application varied from 4 times a day (22) to 2 times a week (20), no adverse effects were reported. In both studies there was a shorter healing time when ozonated oil was introduced.

Ozonated oil in subprosthetic stomatitis

Three (15, 17, 22) of the studies included in this SR (non-RCT) used ozonated oil as treatment for subprosthetic stomatitis and compared it with conventional treatment consisting of nystatin. The follow-up time ranged from 7 days (17, 22) to 15 days (15), on the other hand, the interval of application of ozonated oil for this type of injury varied from once a day (15, 17) to 2 times a day (22). The healing time found in the studies varied from 7 days (17, 22) up to 12 days (15). In all the studies, there was a shorter recovery time when Ozonated oil was used as therapy compared with treatment with nystatin. No adverse effects were reported.

Ozonated oil in recurrent

aphthous stomatitis

In 3 RCTs (14, 16, 19) and 2 non-RCT (21, 22) studies the Ozonated oil was used to treat recurrent aphthous stomatitis and compared it with other therapies such as: multivitamins and 0.2% chlorhexidine mouthwashes (14, 19), sodium perborate alkaline mouthwashes and 0.2% chlorhexidine mouthwashes (16, 22), and finally a comparative study with metronidazole gel (21), with a follow-up time ranging from 7 (14, 16, 19, 22) to 14 days (21), an interval of application of between 2 (14, 19, 22) to 4 (16, 21) times a day, as a healing time between 5 (14) and 7 days (16, 19, 21, 22). In all cases, a shorter recovery time was observed when Ozonated oil was implemented as therapy. Only 2 studies (19, 21) reported statistically significant differences. No adverse effects were reported.

Ozonated oil in herpetic gingivoestomatitis

Only 1 non RCT study (13) included in the present SR used the Ozonated oil as therapy for herpetic gingivoestomatitis and compared it with the use of idoxuridine at 0.1% with a follow-up period of 10 days, the healing time was ≤8 days for the control group, the interval of application was once a day, without specifying the presence of the adverse effects. The patients treated with the Ozonated oil had a shorter healing time of the lesion.

Risk of bias in the studies selected

In RCT studies, inadequate methods of generating sequences and assigning participants were found in all of the publications (90%) included and only one study showed a correct assignment process between groups (Figure 2). Among the deviations from the planned interventions, 60% of the studies were classified as "high" due to problems with the masking process (Figure 3). However, it was not possible to mask the entire staff due to the experimental context. Finally, all studies reported results without a pre-specified plan. In general, it was considered that only one study had a clear risk of bias. Figures 2 and 3 show a summary of the results.

Three of the non-RCT studies were classified as having a severe risk of bias (15-17), one study with a moderate risk of bias (21) and one study was classified as having a critical risk of bias (13) as shown in Figure 4.

DISCUSSION

In this SR, the effect of Ozonated oil was studied in oral lesions such as subprosthetic stomatitis, recurrent aphthous stomatitis, herpetic gingivostomatitis, pericoronitis, alveolitis and fibroedematous gingivitis. Despite the differences of the oral lesions described, there was always a positive therapeutic effect when using ozonated oil when compared with the corresponding conventional treatment. In many cases this effect was reflected as a shorter healing time or less discomfort for the patient. In the majority of the studies included, the lack of adverse effects was another point favoring Ozonated oil, showing to be a safe therapy for patients.

Relative to pericoronitis, in a SR about the standard of care for pericoronitis based on evidence, Wehr et al. (28). informed that receiving antibiotics and follow-up appointment was the most common treatment option for these cases. In spite of this, in the 3 studies included in the present SR, which were related to this event, trichloroacetic acid and 0.2% chlorhexidine mouthwashes were used and compared with the local use of the Ozonated oil, showing the latter reduced healing times with statistically significant differences (11, 12).

Alvogyl is widely used for the treatment of alveolitis. However, Alexander (29) and Bloomer (30) do not recommend it for this type of condition. Furthermore, in this SR the superiority of Ozonated oil was shown when compared with the Alvogyl with positive results in a shorter time (5). It is worth mentioning that other studies have shown some other products that produced better results than those of alvogyl. For example, Taberner et al. (31) in a SR concerning the methods used for the management of dry alveolitis, recommending laser therapy, eugenol zinc oxide and growth factor-rich plasma; whereas, Ozonated oil appears to be a simpler alternative than the growth factors-rich plasma since the Ozonated oil costs less and even allows patients to apply the product on themselves (28).

Regarding fibro edematous gingivitis, Gawron et al. (32), in their review, mentioned that the routine treatment of this type of lesion - when it is minimal and local- is based on maintaining proper oral hygiene and performing a scaling and root planing. For diffuse and advanced gingival enlargement, however, surgical intervention is necessary, with the indication of chlorhexidine mouthwashes in all cases, and the recommendation is to investigate less invasive therapeutic methods. In the present SR, there are 2 studies (20, 22) in which the Ozonated oil, combined with a good oral hygiene, obtained favorable results and a shorter healing time when compared with the use of chlorhexidine. This could be debated considering the great antibacterial effect that has been reported for Ozonated oil in some microbiological studies (33, 34). In the cited studies, the potential of Ozonated oil to reduce the presence of periodontal pathogens and other opportunistic bacteria was shown to be equally effective than chlorhexidine (33, 34).

Subprosthetic stomatitis is regularly treated with nystatin, as its efficacy for treatment of this disease has been shown in several studies (35). Nevertheless, despite the afore-mentioned favorable results, 3 studies included in this SR compared the use of nystatin with ozonated oil (15, 17, 22), in which patients achieved recovery in a shorter time interval in study group (ozone oil). It is worth to mentioned that ozone oil not only has antimicrobial and anti-fungal properties, but also stimulates the immune system and promotes a site-specific wound healing (36).

Recurrent aphthous stomatitis (RAS) is the most common lesion in the oral mucosa, and although its natural history has shown that it is cured without any damage, the most severe forms need a treatment focused on reducing the pain and promoting the healing of ulcers (8,12). Corticosteroids are normally used, as well as topical application of chlorhexidine, tetracycline and diluted hydrogen peroxide (37, 38). Although there is no evidence of the bacterial origin of recurrent aphthous stomatitis, in this SR, in the 5 studies that tested treatments for this type of lesion (14, 16, 19, 21, 22), the majority compared the use of ozonated oil with local application of chlorhexidine and vitaminic supplements taken orally. The findings showed that compared with Ozonated oil, the treatments tested needed longer recovery times. These results could be associated with the antimicrobial and healing properties of the Ozonated oil (36), conferring a therapeutical advantage on it.

Herpetic gingivostomatitis is an oral lesion common in children and it is usually treated by controlling the symptoms and complemented by oral administration of Acyclovir (39, 40). In one study included in this SR, the authors used an anti-viral agent (idoxuridine) and showed a longer recovery time when compared with the Ozonated oil. In spite of the fact that there is no evidence of Ozonated oil having any antiviral properties, its known properties of promoting and improving healing (36) allowed a quick recovery of patients, once the viral cycle of the disease had passed.

In this SR there was diversity of information and methodology of the studies included that did not allow a metanalysis to be performed. The poor methodology was reflected in the high risk of bias. Therefore, the authors suggest that more clinical studies with higher standards of methodological rigor, need to be conducted. However, in spite of the diverse presentations in the studies selected, it was possible to observe advantages for the use of Ozonated oil in the treatment of oral lesions, achieving faster healing and the absence of adverse effects. As a result, the authors suggest that the use of ozone oil should be widely divulged throughout the dental community and scientific world, so that it may have a promising future in different types of treatment in our specialty.

CONCLUSION

In summary, in spite of the limited information found and the lack of methodological meticulousness of the included studies included in this SR, it was suggested that positive effects were obtained with the use of ozonated oil for the treatment of oral lesions, when compared with conventional alternatives. This effect on various types of oral lesions was found to be beneficial in terms of shorter healing times and no adverse effects, presenting a safe and reliable alternative treatment for patients suffering from soft tissue lesions.

Conflict of interest

The authors show no conflict of interest with respect to the article.

Financing

Self-funded.

AUTHOR CONTRIBUTION STATEMENT

Conceptualization and design: J.Y.C. and J.M.M.

Literature review: J.Y.C. and G.M.A.

Methodology and validation: J.Y.C., Y.C.R. and G.M.A.

Formal analysis: J.Y.C., Y.C.R. and J.M.M.

Investigation and data collection: J.Y.C.

Resources: J.Y.C. and G.M.A.

Data analysis and interpretation: J.Y.C., Y.C.R. and J.M.M.

Writing-original draft preparation: J.Y.C., and Y.C.R.

Writing-review & editing: J.Y.C., Y.C.R. and J.M.M.

Supervision: G.M.A and J.M.M.

Project administration: G.M.A.

Funding acquisition: J.Y.C.

REFERENCES

1. Kramer I.R., Pindborg J.J., Bezroukov V., Infirri J.S. Guide to epidemiology and diagnosis of oral mucosal diseases and conditions. World Health Organization. Community dentistry and oral epidemiology. 1980; 8 (1): 1-26. DOI: 10.1111/j.1600-0528.1980.tb01249.x

2. El Toum S., Cassia A., Bouchi N., Kassab I. Prevalence and Distribution of Oral Mucosal Lesions by Sex and Age Categories: A Retrospective Study of Patients Attending Lebanese School of Dentistry. International journal of dentistry. 2018; 2018: 4030134. DOI: 10.1155/2018/4030134

3. Krishna Priya M., Srinivas P., Devaki T. Evaluation of the Prevalence of Oral Mucosal Lesions in a Population of Eastern Coast of South India. Journal of International Society of Preventive & Community Dentistry. 2018; 8 (5): 396-401. DOI: 10.4103/jispcd.JISPCD_207_17

4. Cruz Quintana S.M., Díaz Sjostrom P., Arias Socarrás D., Mazón Baldeón G.M. Microbiota de los ecosistemas de la cavidad bucal. Revista Cubana de Estomatología. 2017; 54: 84-99.

5. Martinez-Abreu J., Guerra-Fonten N., Blanco-Garcia A., Naranjo-Rodrigo S., Llanes-Llanes E., Menendez-Cepero S. Efficacy of OLEOZON® compared to Alvogil in the treatment of alveolitis. Journal of Ozone Therapy. 2015. 2015; 1 (1): 1-8.

6. Tiwari S., Avinash A., Katiyar S., Aarthi Iyer A., Jain S. Dental applications of ozone therapy: A review of literature. The Saudi Journal for Dental Research. 2017; 8 (1): 105-11. http://dx.doi.org/10.1016/j.sjdr.2016.06.005

7. Martis E., Ekta J. Ozone therapy: A clinical review. Journal of Natural Science, Biology and Medicine. 2011; 2: 66-70. DOI: 10.4103/0976-9668.82319

8. Díaz Gómez M.F., Ledea Lozano O.E., Gómez Regüeiferio M., Garcés Mancheño R., Alaiz Barragán M.S., Martínez Force E. Estudio comparativo de la ozonización de aceites de girasol modificados genéticamente y sin modificar. Química Nova. 2009; 32: 2467-72. https://doi.org/10.1590/S0100-40422009000900041

9. Menéndez S., Falcón L., Maqueira Y. Therapeutic efficacy of topical OLEOZON® in patients suffering from onychomycosis. Mycoses. 2011; 54 (5): e272-7. https://doi.org/10.1111/j.1439-0507.2010.01898.x

10. Travagli V., Zanardi I., Valacchi G., Bocci V. Ozone and Ozonated Oils in Skin Diseases: A Review. Mediators of Inflammation. 2010; 2010: 610418. DOI: 10.1155/2010/610418

11. Mayor Hernández F., Moure Ibarra M.D., García Valdés M.R. Evolución clínica de las pericoronaritis tratadas con OLEOZON® en urgencias estomatológicas. Revista Médica Electrónica. 2010; 32 (2): 1-7.

12. Mayor Hernández F., Martínez Abreu J., Moure Ibarra M.D., García Valdés M.R. Aplicación del OLEOZÓN® en el tratamiento de las pericoronaritis. Revista Médica Electrónica. 2011; 33: 75-80.

13. Rodríguez Corona O., Hernández Sánchez Y. Eficacia del oleozón en el tratamiento de la gingivoestomatitis herpética aguda en pacientes pediátricos. Correo Científico Médico. 2012. 2012; 16 (1): 1-2.

14. Fontaine Machado O., Fontaine Uliver Md.C., Pérez Alfonzo D.O., Núñez Oduardo E.A., García Jiménez A.M. El Oleozón en el Tratamiento de la Estomatitis Aftosa. Revista Científica Hallazgos 21. 2016; 1 (2): 125-135.

15. Castillo Betancourt E.O.C.M., Yuniel Hernández J., Castillo Fernandez E. Estomatitis subprotésica y efectividad del oleozón en su tratamiento. RCOE. 2018; 23 (4): 117-123.

16. Díaz-Couso Y., Arias-Pérez Y., Garrido-Labrada M., Reyes-Nieblas J., Tamayo-Ricardo C.M. Ozonoterapia en pacientes mayores de 12 años con estomatitis aftosa recurrente. Revista Electrónica Dr. Zoilo E. Marinello Vidaurreta; 2018; 43 (6): 1-6.

17. Jiménez López Y., Matos Cantillo D.M., Pita Laborí L.Y., De la Cruz Muguercia M. Matos Cantillo C.C. Efectividad del Oleozón® tópico en la estomatitis subprótesis. Revista Información Científica. 2018; 97: 261-9.

18. Souto Román Md.C., Luis Téllez C., Rosales Corria E.N., Gómez Reyes Z. Aplicación del ozono en alveolitis dentaria. 2018. 2018; 22 (1): 11.

19. Leal Rodríguez M.I., Leyva Céspedes N., Zamora Guevara N. Efectividad del oleozón en el tratamiento de la estomatitis aftosa recurrente. Mediciego;2018; 25 (3): 8.

20. Peña Rosell A., Capote Femenías J.L., Jover Capote N. Utilidad del oleozón tópico en la gingivitis crónica fibroedematosa. Revista Médica Electrónica. 2019; 41: 54-62.

21. Alexandrina E., Poroyskiy S., Makedonova Y., Veremeenko S. Efficacy of ozone therapy in treatment of erosive and ulcerative lesions of oral mucosa. Archivo Euromedica. 2020; 10 (2): 67-69. http://dx.doi.org/10.35630/2199-885X/2020/10/2.20

22. Díaz-Couso Y. Efectividad de la ozonoterapia en el tratamiento de enfermedades bucales en pacientes de un área de salud. Revista Electrónica Dr Zoilo E Marinello Vidaurreta. 2020; 45 (5): 1-7.

23. Moher D., Liberati A., Tetzlaff J., Altman D.G., Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009; 62 (10): 1006-12. https://doi.org/10.1136/bmj.b2535

24. Shea B.J., Hamel C., Wells G.A., Bouter L.M., Kristjansson E., Grimshaw J., et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009; 62 (10): 1013-20. DOI: 10.1016/j.jclinepi.2008.10.009

25. Greenhalgh T., Peacock R. Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources. BMJ. 2005; 331 (7524): 1064-5. DOI: 10.1136/bmj.38636.593461.68

26. Sterne J.A.C., Savović J., Page M.J., Elbers R.G., Blencowe N.S., Boutron I., et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet]. 2019 2019/08//; 366: [l4898 p.]. Available from: http://europepmc.org/abstract/MED/31462531, https://doi.org/10.1136/bmj.l4898.

27. Sterne J.A., Hernán M.A., Reeves B.C., Savović J., Berkman N.D., Viswanathan M., et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. doi: https://doi.org/10.1136/bmj.i4919

28. Wehr C., Cruz G., Young S., Fakhouri W.D. An Insight into Acute Pericoronitis and the Need for an Evidence-Based Standard of Care. Dentistry journal. 2019; 7 (3): 88. DOI: 10.3390/dj7030088

29. Alexander R.E. Dental extraction wound management: a case against medicating postextraction sockets. J Oral Maxillofac Surg. 2000 May; 58 (5): 538-51. doi: 10.1016/s0278-2391(00)90017-x

30. Bloomer C.R. Alveolar osteitis prevention by immediate placement of medicated packing. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000; 90 (3): 282-4. DOI: 10.1067/moe.2000.108919

31. Taberner-Vallverdú M., Nazir M., Sánchez-Garcés M., Gay-Escoda C. Efficacy of different methods used for dry socket management: A systematic review. Medicina oral, patologia oral y cirugia bucal. 2015; 20 (5): e633-9. doi: 10.4317/medoral.20589

32. Gawron K., łazarz-bartyzel K., Potempa J., Chomyszyn-Gajewska M. Gingival fibromatosis: Clinical, molecular and therapeutic issues. Orphanet Journal of Rare Diseases. 2016; 11: 9.

33. Huth K., Quirling M., Lenzke S., Paschos E., Kamereck K., Brand K., et al. Effectiveness of ozone against periodontal pathogenic microorganisms. European journal of oral sciences. 2011; 119: 204-10. DOI: 10.1111/j.1600-0722.2011.00825.x

34. Montevecchi M., Dorigo A., Cricca M., Checchi L. Comparison of the antibacterial activity of an ozonated oil with chlorhexidine digluconate and povidone-iodine. A disk diffusion test. The new microbiologica. 2013; 36 (3): 289-302.

35. Hilgert J.B., Giordani J.M., de Souza R.F., Wendland E.M., D'Avila O.P., Hugo F.N. Interventions for the Management of Denture Stomatitis: A Systematic Review and Meta-Analysis. Journal of the American Geriatrics Society. 2016; 64 (12): 2539-45. DOI: 10.1111/jgs.14399

36. Anzolin A.P., da Silveira-Kaross N.L., Bertol C.D. Ozonated oil in wound healing: what has already been proven? Med Gas Res. 2020 Jan-Mar; 10 (1): 54-59. doi: 10.4103/2045-9912.279985

37. Giannetti L., Murri Dello Diago A., Lo Muzio L. Recurrent aphtous stomatitis. Minerva stomatologica. 2018; 67 (3): 125-8. DOI: 10.23736/S0026-4970.18.04137-7

38. Cui R.Z., Bruce A.J., Rogers R.S., 3rd. Recurrent aphthous stomatitis. Clinics in dermatology. 2016; 34 (4): 475-81. DOI: 10.1016/j.clindermatol.2016.02.020

39. Mohan R.P., Verma S., Singh U., Agarwal N. Acute primary herpetic gingivostomatitis. BMJ case reports. 2013; 2013: bcr2013200074.

40. Goldman R.D. Acyclovir for herpetic gingivostomatitis in children. Can Fam Physician. 2016 May; 62 (5): 403-4.